Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Corvus Pharma Com (NQ: CRVS )

2.160 -0.020 (-0.92%)
Streaming Delayed Price Updated: 2:37 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 29,858
Open 2.170
Bid (Size) 2.170 (2)
Ask (Size) 2.180 (2)
Prev. Close 2.180
Today's Range 2.140 - 2.200
52wk Range 1.050 - 2.690
Shares Outstanding 62,551
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
One of the best ways to spot opportunity in penny stocks to buy is by following insiders. Here are three to consider. 
Via InvestorPlace
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+22.73%
+22.73%
1 Month
+21.35%
+21.35%
3 Month
+50.00%
+50.00%
6 Month
+5.37%
+5.37%
1 Year
-10.74%
-10.74%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 19, 2024
Via Benzinga
Earnings Outlook For Corvus Pharma
Via Benzinga
Preview: Corvus Pharma's Earnings
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Toro Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer
Via Benzinga
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.